Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluzone: Influenza virus vaccine · 1 trial · 1 indication
Pain or other discomfort was assessed on a scale of 0 to 10 (None = 0; Hardly Any = 1, 2; Mild = 3, 4; Moderate = 5, 6; Severe = 7, 8; Unbearable = 9, 10) according to route of administration: intradermal (ID) as Group 1 and intramuscular (IM) as Group 2. Data for this outcome were combined for responses following a similar type of vaccination route in the entire study population.
Numerical scores were assigned to pain by participants on the preference questionnaire as: None = 0; Hardly Any = 1, 2; Mild = 3, 4; Moderate = 5, 6; Severe = 7, 8; or Unbearable = 9, 10. Data for this outcome were combined for responses following a similar type of vaccination route in the entire study population.
| Arm | Type | Description |
|---|---|---|
| Fluzone Intradermal First, Then Fluzone Intramuscular | EXPERIMENTAL | - |
| Fluzone Intramuscular First, Then Fluzone Intradermal | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fluzone: Influenza virus vaccine | BIOLOGICAL | 0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid |
Inclusion Criteria: * Healthy male or female subject (can have underlying medical condition, as long as they are stable), greater than or equal to 18 to \< 50 years of age on the day of inclusion. * Informed consent form signed. * Able to attend both scheduled visits and to comply with all trial pr...
Fluzone is an influenza virus vaccine used to prevent influenza. It is being studied in healthy adults in the United States. The vaccine is administered either intradermally or intramuscularly, and a clinical trial is evaluating patient preference for these two routes of administration.
Fluzone is developed by Sanofi, a company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical research on this influenza vaccine to assess its use in healthy adult populations.
Fluzone is in Phase 2 clinical development. A Phase 2 trial has been completed, which studied the vaccine in healthy adults for the prevention of influenza. The vaccine remains investigational and is not yet approved for widespread use.
Fluzone has one completed Phase 2 clinical trial registered under NCT00623181. This study, titled "Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults," enrolled 110 participants in the United States. The trial was controlled but not double-blinded.
Yes, Fluzone is an influenza virus vaccine. It is designed to protect against influenza, a viral infection of the respiratory tract. The vaccine is being evaluated in clinical trials to determine its effectiveness and tolerability in healthy adults.